1) not true, revenues have been increasing if you look at...

1) not true, revenues have been increasing if you look at Appendices, admittedly still low in absolute terms, but increasing (4Q 21 was +73% YoY, 3Q 21 was +99% YoY)
2) not true on big Pharma interest, J&J has funded a stage II trial of its autologous stem cell therapy, further results on which are due out imminently (company advised 1st/2nd qtr). There are dozens of ASX bio-tech companies trading at far higher mkt caps, with no such formal big pharma trial sponsorship, let alone alleged informal interest
3) of course its balance sheet is slowly decreasing, its a early stage, pre-cash flow positive medical company beginning to commercialise it products, but its cash burn is far better than many companies that are only phase I/II and unlike them it has two products approved with the TGA, and one with the FDA and EMA already
4) retail and insto's vote pay increases, stock and stock option rewards all the time at AGM with little thought, its the capitalist shareholder AGM remuneration standard across all ASX companies and again, OCC hardly any different and at the lower end of the scale

Sorry HotDog, but with respect, you are invested in phase II/III bio-tech that is beginning on the long road to commercialisation, but is well placed with multiple products approvals in place already. If OCC was formally commercially partnered and cash flow positive, you'd more likely be paying $4.00 for OCC rather than $0.40. I notice you have invested in IMU. I like IMU, nearly bought in ages ago myself but missed being filled on a low ball order ahead of Dr Rita Laeufle's trial success reporting in April 2021 - the stock took off after and I missed a nice little earner (glad to see you didn't buy-in at $0.62 and presumably low 30's instead)

If these are your (slightly misinformed) complaints about OCC, I fear you will be similarly dissapointed in IMU. Its a phase I/II company behind OCC in the regulatory/commercialisation curve (IMU's phase II research HER-Vaxx partnerhsip with Merck not dissimilar to OCC's ATI trial with J&J). IMU is burning through cash far faster at around $30 million a year in cash and OCC looks positively thrifty by comparison as a stage II/III company. I do suspect you will ultimately be successful in both companies if you have the patience, but at $80 million mkt cap vs its forward earnings potential, OCC to me is a far more favourable investment prospect than the $1.35 billion mkt cap of IMU. Investing in both will alas test the patience of a Saint. I wish you good fortune in both.